{"name":"Advancis Pharmaceutical Corporation","slug":"advancis-pharmaceutical-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Amoxicillin Pulsatile Release Multiparticluate Sprinkle","genericName":"Amoxicillin Pulsatile Release Multiparticluate Sprinkle","slug":"amoxicillin-pulsatile-release-multiparticluate-sprinkle","indication":"Bacterial infections susceptible to amoxicillin (specific indications in Phase 3 development unknown)","status":"phase_3"}]}],"pipeline":[{"name":"Amoxicillin Pulsatile Release Multiparticluate Sprinkle","genericName":"Amoxicillin Pulsatile Release Multiparticluate Sprinkle","slug":"amoxicillin-pulsatile-release-multiparticluate-sprinkle","phase":"phase_3","mechanism":"Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, delivered via a pulsatile release multiparticulate sprinkle formulation for modified pharmacokinetics.","indications":["Bacterial infections susceptible to amoxicillin (specific indications in Phase 3 development unknown)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2024-12-04","type":"pipeline","source":"Medical Dialogues","summary":"Six Pharma Suppliers Blacklisted in Five Years for Failing Quality Standards: MoS Anupriya Patel - Medical Dialogues","headline":"Six Pharma Suppliers Blacklisted in Five Years for Failing Quality Standards: MoS Anupriya Patel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBKOFBNWlZ6XzZKYktMREY1bEFRUEpjSzFNYjZkV01RWFJOYXM5WTJkdVJYMEVuM0V1eWthRTFoeDhfWmItalJESGN0clNlVFJUNDlTa0ZWWVN5bTNxVnVXX3FfWjVLaHU0T2Q1aw?oc=5","date":"2022-01-12","type":"pipeline","source":"Pharma Voice","summary":"Talent Pool - Pharma Voice","headline":"Talent Pool","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNeDRkVzc1SkNrc3UtcGg5RE5uMXA2WHh5NXhwLWk1WW5tQUhLQ0NyRDg0RnRMRkpRWjFRaWNQeVEzRERfM3FfRVdDU3dlMXhMZzFNTnl3VFBRY2R4aU9obkk0T2t3Zlk4QjUzUWtWUDJocnFISFZrMThqUFROX0Vycnl6OW1uZ0N0QTdtMnJaWk1oNmFueEVsRUUyM1dlNmJvM3lYenFUSS14bVMzS0UxM2JhMjN1bDdvdlR0cmNuRXRsYzFNMTNlOXo0aXZ2TEgydEJpNVoyMklicnZoN0ZrckhpbU9BZ01ESXc?oc=5","date":"2020-06-05","type":"pipeline","source":"Institutional Investor","summary":"Investors Seem to Know About Activist Campaigns Before They Happen. Should They? - Institutional Investor","headline":"Investors Seem to Know About Activist Campaigns Before They Happen. Should They?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFA4MmFuWmFtRkNyZDNmQUx1cXJLa1Z4c2ltd3Y1OVk4M25hRy1RZUpkTWJJRFNxVVkyQUFKUnJmaHNfSVozWXlxRTNhNlNNYldsaFFOaHdIaE9kc01CRjE3UnZ3a29DOUtLblBhMXZGU255WXBzM1N3VnNBWnMzZ1k?oc=5","date":"2004-07-04","type":"deal","source":"The Pharma Letter","summary":"Advancis buys Lilly's Keflex brand for $11M - The Pharma Letter","headline":"Advancis buys Lilly's Keflex brand for $11M","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}